Agentix Corp (PK:AGTX)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 32932 PACIFIC COAST HIGHWAY, #14-254
DANA POINT CA 92629
Tel: N/A
Website: https://agentixcorp.com
IR: See website
<
Key People
Salman Hoda
President, Chief Executive Officer, Treasurer, Company Secretary, Director 		   
Business Overview
Agentix Corp. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic agents for the treatment of metabolic diseases like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM). AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease. The Company is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is the regulatory system which governs metabolism. The Company's wholly owned subsidiaries include GSL Healthcare, Inc., Agentix Australia Pty Ltd, and Applied Biopharma LLC.
Financial Overview
For the nine months ended 31 December 2023, Agentix Corp revenues was not reported. Net loss decreased 38% to $582K. Lower net loss reflects Research and development decrease of 76% to $129K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.02 to -$0.01.
Reporting Currency: U.S. Dollars
Enterprise value: $1.39M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$1.20M as of Dec 31, 2023
Net annual income (TTM): -$1.01M as of Dec 31, 2023
Free cash flow (TTM): -$0.09M as of Dec 31, 2023
Net Debt Last Fiscal Year: $0.10M as of Dec 31, 2023
Shares outstanding: 40,066,931 as of Feb 7, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More